Trial Profile
Feasibility study of adjuvant chemotherapy with carboplatin and nab-paclitaxel for resected NSCLC
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 03 Dec 2019
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 02 Dec 2019 Status changed from recruiting to completed.
- 06 Oct 2013 New trial record